DLK1 and adrenal cortex carcinoma: Apart from ACC, we found that DLK1 is more heterogeneously expressed in NE cancers such as SCLC, suggesting further insights into mechanisms of DLK1 expression, particularly epigenetic mechanisms that may control DLK1 imprinting, will be important for the development of potential future DLK1-targeted combination therapies.